- Home
- FUSE vs MIRA Comparison
FUSE vs MIRA Comparison
Compare FUSE & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FUSE | MIRA |
|---|---|---|
| Founded | 2013 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.2M | 50.3M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | FUSE | MIRA |
|---|---|---|
| Price | $1.73 | $1.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 10.9M | 170.3K |
| Earning Date | 06-05-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,949,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.87 | N/A |
| 52 Week Low | $1.45 | $0.73 |
| 52 Week High | $25.00 | $2.45 |
Technical Indicators
Market Signals| Indicator | FUSE | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 45.91 | 34.16 |
| Support Level | $1.65 | $1.13 |
| Resistance Level | $2.13 | $1.25 |
| Average True Range (ATR) | 0.35 | 0.07 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 6.84 | 16.18 |
Price Performance
Historical ComparisonAbout FUSE Fusemachines Inc.
Fusemachines Inc is a provider of enterprise AI products and solutions. The company provides good quality AI education in underserved communities and helping organizations achieve their full potential with AI. The products of the company include AI Studio, Answer Gen, GenAI Engines, and others.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.